» Articles » PMID: 22046250

Proteasomal Degradation of P53 by Human Papillomavirus E6 Oncoprotein Relies on the Structural Integrity of P53 Core Domain

Overview
Journal PLoS One
Date 2011 Nov 3
PMID 22046250
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The E6 oncoprotein produced by high-risk mucosal HPV stimulates ubiquitinylation and proteasome-dependent degradation of the tumour suppressor p53 via formation of a trimeric complex comprising E6, p53, and E6-AP. p53 is also degraded by its main cellular regulator MDM2. The main binding site of p53 to MDM2 is situated in the natively unfolded N-terminal region of p53. By contrast, the regions of p53 implicated in the degradation by viral E6 are not fully identified to date. Here we generated a series of mutations (Y103G, Y107G, T155A, T155V, T155D, L264A, L265A) targeting the central folded core domain of p53 within a region opposite to its DNA-binding site. We analysed by in vitro and in vivo assays the impact of these mutations on p53 degradation mediated by viral E6 oncoprotein. Whereas all mutants remained susceptible to MDM2-mediated degradation, several of them (Y103G, Y107G, T155D, L265A) became resistant to E6-mediated degradation, confirming previous works that pointed to the core domain as an essential region for the degradation of p53. In parallel, we systematically checked the impact of the mutations on the transactivation activity of p53 as well as on the conformation of p53, analysed by Nuclear Magnetic Resonance (NMR), circular dichroism (CD), and antibody probing. These measurements suggested that the conformational integrity of the core domain is an essential parameter for the degradation of p53 by E6, while it is not essential for the degradation of p53 by MDM2. Thus, the intracellular stability of a protein may or may not rely on its biophysical stability depending on the degradation pathway taken into consideration.

Citing Articles

Human Viral Oncoproteins and Ubiquitin-Proteasome System.

Atani Z, Hosseini S, Goudarzi H, Faghihloo E Glob Med Genet. 2024; 11(4):285-296.

PMID: 39224462 PMC: 11368560. DOI: 10.1055/s-0044-1790210.


High-Grade Serous Ovarian Cancer-A Risk Factor Puzzle and Screening Fugitive.

Wilczynski J, Paradowska E, Wilczynski M Biomedicines. 2024; 12(1).

PMID: 38275400 PMC: 10813374. DOI: 10.3390/biomedicines12010229.


The E3 Ligases in Cervical Cancer and Endometrial Cancer.

Zhai F, Wang J, Yang W, Ye M, Jin X Cancers (Basel). 2022; 14(21).

PMID: 36358773 PMC: 9658772. DOI: 10.3390/cancers14215354.


Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of Tumour Suppressor Activities.

Makgoo L, Mosebi S, Mbita Z Front Mol Biosci. 2022; 9:875208.

PMID: 35620479 PMC: 9127998. DOI: 10.3389/fmolb.2022.875208.


Incidence of betapapillomaviruses in the tumour and perilesional healthy skin in patients with basal cell carcinoma depending on sex, age, hair colour, tumour subtype, its location and dissemination.

Sitarz K, Kopec J, Szostek S, Sulowicz J Postepy Dermatol Alergol. 2021; 38(5):866-872.

PMID: 34849136 PMC: 8610056. DOI: 10.5114/ada.2020.98877.


References
1.
Kussie P, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine A . Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996; 274(5289):948-53. DOI: 10.1126/science.274.5289.948. View

2.
Kastan M, Zhan Q, El-Deiry W, Carrier F, Jacks T, Walsh W . A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992; 71(4):587-97. DOI: 10.1016/0092-8674(92)90593-2. View

3.
Talis A, Huibregtse J, Howley P . The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem. 1998; 273(11):6439-45. DOI: 10.1074/jbc.273.11.6439. View

4.
Maki C, Huibregtse J, Howley P . In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996; 56(11):2649-54. View

5.
Cho Y, Gorina S, Jeffrey P, Pavletich N . Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 1994; 265(5170):346-55. DOI: 10.1126/science.8023157. View